Mariana Oncology Inc

Vigil will use the Series A funds to progress its lead pipeline candidate, a monoclonal antibody TREM2 agonist, through Phase 1 studies, advance their small molecule TREM2 agonist to IND, as well as pursue additional assets to grow the pipeline and increase the body of data supporting microglia biology as an important therapeutic pathway.

Remix Therapeutics is a clinical-stage biotechnology company based in Watertown, MA, focused on developing small molecule therapies that modulate RNA processing to address the underlying drivers of diseases, particularly in the oncology space. Founded in 2020, the company aims to transform patients' lives by creating new therapeutic options for conditions with high unmet medical needs. With a proprietary drug discovery platform, Remix Therapeutics harnesses cellular machinery to control RNA processing and identify druggable targets. The company's commitment to scientific integrity and urgency is driven by the belief that patients are counting on innovative solutions to improve their outcomes. Generated from the website

MelliCell Inc. is a biotechnology company based in Watertown, MA, specializing in pioneering adipocyte therapies for chronic diseases through innovative fat cell engineering technology. Their mission is to harness the potential of mature human fat cells to develop therapeutic solutions aimed at improving the health and lives of individuals suffering from conditions such as diabetes and obesity. With a commitment to integrity, respect, and collaboration, MelliCell partners with leading biomedical organizations like Mass General Brigham to advance their research initiatives. Recently awarded a prestigious SEED grant from the National Institutes of Health, the company is poised to accelerate the development of novel biologic drugs and therapeutic approaches that address the growing global health challenges associated with chronic diseases. Generated from the website